3The Evidence Base and Clinical Guidelines

FWhy guidelines matter in a field full of claims

Tinnitus attracts an unusually large number of unproven remedies, from herbal pills to clinic-marketed devices. Clinical practice guidelines exist to cut through this noise by grading the actual evidence and translating it into recommendations. For tinnitus, two documents dominate: the 2014 American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS) clinical practice guideline and the 2019 multidisciplinary European guideline [2014] [2019].

Reassuringly, despite different methods and health systems, the two agree on the essentials. This convergence gives clinicians confidence that the recommendations reflect the evidence rather than local opinion.

TWhat the AAO-HNS 2014 guideline recommends

The AAO-HNS guideline applies to persistent (six months or longer), bothersome primary tinnitus. It recommends that clinicians provide education to all such patients; recommend a hearing-aid evaluation for those with coexisting hearing loss; and recommend cognitive behavioural therapy. Sound therapy may be offered as an option [2014].

Equally important are its negative recommendations. The guideline recommends against routine antidepressants, anticonvulsants, anxiolytics and intratympanic drugs for the express purpose of treating the tinnitus itself; against ginkgo biloba, melatonin and zinc supplements; against transcranial magnetic stimulation; and against routine imaging in patients without focal neurological signs, pulsatile or unilateral tinnitus. These “do-not” statements are as clinically valuable as the positive ones.

TThe 2019 European multidisciplinary guideline

The European guideline takes a multidisciplinary, stepped-care perspective spanning diagnostics, assessment and treatment. It endorses structured assessment of tinnitus impact, education, and psychological therapy — particularly CBT — as the interventions with the strongest evidence, delivered within a tiered service from primary care to specialist teams [2019].

Like the AAO-HNS, it does not endorse any drug or supplement as a treatment for the tinnitus percept. Its distinctive contribution is the emphasis on organising care across disciplines and matching treatment intensity to impact severity rather than to the mere presence of the sound.

CWhy CBT carries the strongest recommendation

Both guidelines single out cognitive behavioural therapy because it has the most robust evidence of any tinnitus intervention. Meta-analysis of randomised controlled trials shows that CBT meaningfully reduces tinnitus-related distress and improves quality of life, even though it does not change the loudness of the sound [2011]. A Cochrane review reached the same conclusion, finding moderate-certainty evidence that CBT reduces the negative impact of tinnitus on quality of life [2020].

This is the evidence base in microcosm: the interventions that work are those that change the brain’s response to the sound, not those that chase the sound itself. It also explains why guidelines place CBT, education and amplification above every pharmacological option.

CThe honest message: no pharmacological cure

The most important conclusion a clinician can draw from the evidence is also the most sobering: no drug is licensed or proven to cure chronic subjective tinnitus, and large rigorous trials of candidate agents and supplements have repeatedly failed to beat placebo for the percept itself. The updated Cochrane review of ginkgo biloba, for example, found no evidence that it benefits patients whose primary complaint is tinnitus [2022], and the Cochrane review of zinc reached a similarly negative conclusion [2016].

This honesty is not nihilism. Given that tinnitus affects a large share of adults — around one in seven in population surveys [2016] [2022] — clear guidance protects huge numbers of people from ineffective, costly or harmful treatments while directing them toward the education, amplification and psychological therapy that genuinely help.